{"id":393492,"date":"2020-12-04T08:30:17","date_gmt":"2020-12-04T13:30:17","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=393492"},"modified":"2020-12-04T08:30:17","modified_gmt":"2020-12-04T13:30:17","slug":"moderna-announces-amendment-to-supply-agreement-with-the-ministry-of-health-of-israel-to-supply-additional-doses-of-mrna-vaccine-against-covid-19-mrna-1273","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/moderna-announces-amendment-to-supply-agreement-with-the-ministry-of-health-of-israel-to-supply-additional-doses-of-mrna-vaccine-against-covid-19-mrna-1273\/","title":{"rendered":"Moderna Announces Amendment to Supply Agreement with the Ministry of Health of Israel to Supply Additional Doses of mRNA Vaccine Against COVID-19 (mRNA-1273)"},"content":{"rendered":"

<\/p>\n

Moderna Announces Amendment to Supply Agreement with the Ministry of Health of Israel to Supply Additional Doses of mRNA Vaccine Against COVID<\/b>-19 (mRNA-1273)<\/b><\/p>\n

Agreement reflects Moderna\u2019s commitment to make its vaccine available in multiple countries<\/i><\/p>\n

CAMBRIDGE, Mass.–(BUSINESS WIRE<\/a>)–
\nModerna, Inc., (Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced an expanded supply agreement with the Ministry of Health of Israel for an additional 4 million doses of mRNA-1273, Moderna\u2019s vaccine candidate against COVID-19. The Israeli government has now secured 6 million doses of mRNA-1273. This agreement will support the ongoing efforts by the Ministry to secure early access to a COVID-19 vaccine for the people of Israel. The Company has already initiated the rolling regulatory review process with the Ministry of Health in Israel.\n<\/p>\n

\n\u201cWe appreciate the confidence the Government of Israel and the Ministry of Health has shown in mRNA-1273, our COVID-19 vaccine candidate, with this second purchase,\u201d said St\u00e9phane Bancel, Chief Executive Officer of Moderna. \u201cWe are proud of the progress we have made to date on mRNA-1273, including the recent positive primary efficacy analysis of the Phase 3 COVE Study. We will continue our ongoing dialogue with the Ministry of Health in Israel as we seek to develop our vaccine candidate.\u201d\n<\/p>\n

\nOn November 30, Moderna announced<\/a> that the primary efficacy analysis of the Phase 3 study of mRNA-1273 conducted on 196 cases confirmed the high efficacy observed at the first interim analysis. The data analysis indicates a vaccine efficacy of 94.1%. Safety data continue to accrue and the study continues to be monitored by an independent, NIH-appointed Data Safety Monitoring Board (DSMB). Based on prior analysis<\/a>, the most common solicited adverse reactions included injection site pain, fatigue, myalgia, arthralgia, headache, and erythema\/redness at the injection site. Solicited adverse reactions increased in frequency and severity in the mRNA-1273 group after the second dose. The Phase 3 study, known as the COVE study, enrolled more than 30,000 participants in the U.S. and is being conducted in collaboration with NIAID part of the NIH and the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services.\n<\/p>\n

\nModerna continues to scale up its global manufacturing to be able to deliver approximately 500 million doses per year and possibly up to 1 billion doses per year, beginning in 2021. The Company is working with its strategic manufacturing partners, Lonza of Switzerland and ROVI of Spain, for manufacturing and fill-finish outside of the United States. This is a dedicated supply chain to support countries other than the United States that enter into purchase agreements with Moderna.\n<\/p>\n

\nTo learn more about Moderna\u2019s work on mRNA-1273, visit www.modernatx.com\/COVID19<\/a>.\n<\/p>\n

About Moderna<\/b><\/p>\n

\nModerna is advancing messenger RNA (mRNA) science to create a new class of transformative medicines for patients. mRNA medicines are designed to direct the body\u2019s cells to produce intracellular, membrane or secreted proteins that can have a therapeutic or preventive benefit and have the potential to address a broad spectrum of diseases. The company\u2019s platform builds on continuous advances in basic and applied mRNA science, delivery technology and manufacturing, providing Moderna the capability to pursue in parallel a robust pipeline of new development candidates. Moderna is developing therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and cardiovascular diseases, independently and with strategic collaborators.\n<\/p>\n

\nHeadquartered in Cambridge, Mass., Moderna currently has strategic alliances for development programs with AstraZeneca PLC and Merck & Co., Inc., as well as the Defense Advanced Research Projects Agency (DARPA), an agency of the U.S. Department of Defense, and the Biomedical Advanced Research and Development Authority (BARDA), a division of the Office of the Assistant Secretary for Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS). Moderna has been named a top biopharmaceutical employer by Science for the past six years. To learn more, visit www.modernatx.com<\/a>.\n<\/p>\n

Forward-Looking Statements<\/b><\/p>\n

\nThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding: the terms of the Company\u2019s sale of mRNA-1273 to the Israeli Ministry of Health; plans to seek approval from the Ministry of Health for the distribution of mRNA-1273 in Israel; mRNA-1273’s efficacy and its ability to prevent infection or mitigate symptoms of COVID-19; the safety profile for mRNA-1273; and plans for the manufacture of mRNA-1273 and the scale of anticipated production. In some cases, forward-looking statements can be identified by terminology such as \u201cwill,\u201d \u201cmay,\u201d \u201cshould,\u201d \u201ccould,\u201d \u201cexpects,\u201d \u201cintends,\u201d \u201cplans,\u201d \u201caims,\u201d \u201canticipates,\u201d \u201cbelieves,\u201d \u201cestimates,\u201d \u201cpredicts,\u201d \u201cpotential,\u201d \u201ccontinue,\u201d or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. The forward-looking statements in this press release are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond Moderna\u2019s control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements. These risks, uncertainties, and other factors include, among others: the fact that there has never been a commercial product utilizing mRNA technology approved for use; the fact that the rapid response technology in use by Moderna is still being developed and implemented; the safety, tolerability and efficacy profile of mRNA-1273 observed to date may change adversely in ongoing analyses of trial data or subsequent to commercialization; despite having ongoing interactions with the FDA or other regulatory agencies, the FDA or such other regulatory agencies may not agree with the Company\u2019s regulatory approval strategies, components of our filings, such as clinical trial designs, conduct and methodologies, or the sufficiency of data submitted; Moderna may encounter delays in meeting manufacturing or supply timelines or disruptions in its distribution plans for mRNA-1273; whether and when any biologics license applications and\/or emergency use authorization applications may be filed and ultimately approved by regulatory authorities; potential adverse impacts due to the global COVID-19 pandemic such as delays in regulatory review, manufacturing and clinical trials, supply chain interruptions, adverse effects on healthcare systems and disruption of the global economy; and those risks and uncertainties described under the heading \u201cRisk Factors\u201d in Moderna\u2019s most recent Quarterly Report on Form 10-Q filed with the U.S. Securities and Exchange Commission (SEC) and in subsequent filings made by Moderna with the SEC, which are available on the SEC\u2019s website at www.sec.gov<\/a>. Except as required by law, Moderna disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release in the event of new information, future developments or otherwise. These forward-looking statements are based on Moderna\u2019s current expectations and speak only as of the date hereof.\n<\/p>\n

\"\"<\/p>\n

View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20201204005331\/en\/<\/a><\/span><\/p>\n

Media:
\n
<\/b>Colleen Hussey
\n
Director, Corporate Communications
\n
617-335-1374
\n
<\/b>Colleen.Hussey@modernatx.com
\n<\/a><\/p>\n

Investors:
\n<\/b>
Lavina Talukdar
\n
Senior Vice President & Head of Investor Relations
\n
617-209-5834
\n
Lavina.Talukdar@modernatx.com<\/a><\/p>\n

KEYWORDS:<\/b> Massachusetts United States North America Israel Middle East<\/p>\n

INDUSTRY KEYWORDS:<\/b> Science Other Science Biotechnology Research Pharmaceutical Health Infectious Diseases Clinical Trials<\/p>\n

MEDIA:<\/b><\/p>\n\n\n\n\n
Logo<\/b><\/font><\/td>\n<\/tr>\n
\"Logo\"<\/td>\n<\/tr>\n
<\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"

Moderna Announces Amendment to Supply Agreement with the Ministry of Health of Israel to Supply Additional Doses of mRNA Vaccine Against COVID-19 (mRNA-1273) Agreement reflects Moderna\u2019s commitment to make its vaccine available in multiple countries CAMBRIDGE, Mass.–(BUSINESS WIRE)– Moderna, Inc., (Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced an expanded supply agreement with the Ministry of Health of Israel for an additional 4 million doses of mRNA-1273, Moderna\u2019s vaccine candidate against COVID-19. The Israeli government has now secured 6 million doses of mRNA-1273. This agreement will support the ongoing efforts by the Ministry to secure early access to a COVID-19 vaccine for the people … <\/p>\n

Continue reading “Moderna Announces Amendment to Supply Agreement with the Ministry of Health of Israel to Supply Additional Doses of mRNA Vaccine Against COVID-19 (mRNA-1273)”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-393492","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nModerna Announces Amendment to Supply Agreement with the Ministry of Health of Israel to Supply Additional Doses of mRNA Vaccine Against COVID-19 (mRNA-1273) - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/moderna-announces-amendment-to-supply-agreement-with-the-ministry-of-health-of-israel-to-supply-additional-doses-of-mrna-vaccine-against-covid-19-mrna-1273\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Moderna Announces Amendment to Supply Agreement with the Ministry of Health of Israel to Supply Additional Doses of mRNA Vaccine Against COVID-19 (mRNA-1273) - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Moderna Announces Amendment to Supply Agreement with the Ministry of Health of Israel to Supply Additional Doses of mRNA Vaccine Against COVID-19 (mRNA-1273) Agreement reflects Moderna\u2019s commitment to make its vaccine available in multiple countries CAMBRIDGE, Mass.–(BUSINESS WIRE)– Moderna, Inc., (Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced an expanded supply agreement with the Ministry of Health of Israel for an additional 4 million doses of mRNA-1273, Moderna\u2019s vaccine candidate against COVID-19. The Israeli government has now secured 6 million doses of mRNA-1273. This agreement will support the ongoing efforts by the Ministry to secure early access to a COVID-19 vaccine for the people … Continue reading "Moderna Announces Amendment to Supply Agreement with the Ministry of Health of Israel to Supply Additional Doses of mRNA Vaccine Against COVID-19 (mRNA-1273)"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/moderna-announces-amendment-to-supply-agreement-with-the-ministry-of-health-of-israel-to-supply-additional-doses-of-mrna-vaccine-against-covid-19-mrna-1273\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2020-12-04T13:30:17+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20201204005331r1&sid=flmnd&distro=nx&lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/moderna-announces-amendment-to-supply-agreement-with-the-ministry-of-health-of-israel-to-supply-additional-doses-of-mrna-vaccine-against-covid-19-mrna-1273\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/moderna-announces-amendment-to-supply-agreement-with-the-ministry-of-health-of-israel-to-supply-additional-doses-of-mrna-vaccine-against-covid-19-mrna-1273\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Moderna Announces Amendment to Supply Agreement with the Ministry of Health of Israel to Supply Additional Doses of mRNA Vaccine Against COVID-19 (mRNA-1273)\",\"datePublished\":\"2020-12-04T13:30:17+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/moderna-announces-amendment-to-supply-agreement-with-the-ministry-of-health-of-israel-to-supply-additional-doses-of-mrna-vaccine-against-covid-19-mrna-1273\\\/\"},\"wordCount\":1240,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/moderna-announces-amendment-to-supply-agreement-with-the-ministry-of-health-of-israel-to-supply-additional-doses-of-mrna-vaccine-against-covid-19-mrna-1273\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20201204005331r1&sid=flmnd&distro=nx&lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/moderna-announces-amendment-to-supply-agreement-with-the-ministry-of-health-of-israel-to-supply-additional-doses-of-mrna-vaccine-against-covid-19-mrna-1273\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/moderna-announces-amendment-to-supply-agreement-with-the-ministry-of-health-of-israel-to-supply-additional-doses-of-mrna-vaccine-against-covid-19-mrna-1273\\\/\",\"name\":\"Moderna Announces Amendment to Supply Agreement with the Ministry of Health of Israel to Supply Additional Doses of mRNA Vaccine Against COVID-19 (mRNA-1273) - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/moderna-announces-amendment-to-supply-agreement-with-the-ministry-of-health-of-israel-to-supply-additional-doses-of-mrna-vaccine-against-covid-19-mrna-1273\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/moderna-announces-amendment-to-supply-agreement-with-the-ministry-of-health-of-israel-to-supply-additional-doses-of-mrna-vaccine-against-covid-19-mrna-1273\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20201204005331r1&sid=flmnd&distro=nx&lang=en\",\"datePublished\":\"2020-12-04T13:30:17+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/moderna-announces-amendment-to-supply-agreement-with-the-ministry-of-health-of-israel-to-supply-additional-doses-of-mrna-vaccine-against-covid-19-mrna-1273\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/moderna-announces-amendment-to-supply-agreement-with-the-ministry-of-health-of-israel-to-supply-additional-doses-of-mrna-vaccine-against-covid-19-mrna-1273\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/moderna-announces-amendment-to-supply-agreement-with-the-ministry-of-health-of-israel-to-supply-additional-doses-of-mrna-vaccine-against-covid-19-mrna-1273\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20201204005331r1&sid=flmnd&distro=nx&lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20201204005331r1&sid=flmnd&distro=nx&lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/moderna-announces-amendment-to-supply-agreement-with-the-ministry-of-health-of-israel-to-supply-additional-doses-of-mrna-vaccine-against-covid-19-mrna-1273\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Moderna Announces Amendment to Supply Agreement with the Ministry of Health of Israel to Supply Additional Doses of mRNA Vaccine Against COVID-19 (mRNA-1273)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Moderna Announces Amendment to Supply Agreement with the Ministry of Health of Israel to Supply Additional Doses of mRNA Vaccine Against COVID-19 (mRNA-1273) - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/moderna-announces-amendment-to-supply-agreement-with-the-ministry-of-health-of-israel-to-supply-additional-doses-of-mrna-vaccine-against-covid-19-mrna-1273\/","og_locale":"en_US","og_type":"article","og_title":"Moderna Announces Amendment to Supply Agreement with the Ministry of Health of Israel to Supply Additional Doses of mRNA Vaccine Against COVID-19 (mRNA-1273) - Market Newsdesk","og_description":"Moderna Announces Amendment to Supply Agreement with the Ministry of Health of Israel to Supply Additional Doses of mRNA Vaccine Against COVID-19 (mRNA-1273) Agreement reflects Moderna\u2019s commitment to make its vaccine available in multiple countries CAMBRIDGE, Mass.–(BUSINESS WIRE)– Moderna, Inc., (Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced an expanded supply agreement with the Ministry of Health of Israel for an additional 4 million doses of mRNA-1273, Moderna\u2019s vaccine candidate against COVID-19. The Israeli government has now secured 6 million doses of mRNA-1273. This agreement will support the ongoing efforts by the Ministry to secure early access to a COVID-19 vaccine for the people … Continue reading \"Moderna Announces Amendment to Supply Agreement with the Ministry of Health of Israel to Supply Additional Doses of mRNA Vaccine Against COVID-19 (mRNA-1273)\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/moderna-announces-amendment-to-supply-agreement-with-the-ministry-of-health-of-israel-to-supply-additional-doses-of-mrna-vaccine-against-covid-19-mrna-1273\/","og_site_name":"Market Newsdesk","article_published_time":"2020-12-04T13:30:17+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20201204005331r1&sid=flmnd&distro=nx&lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/moderna-announces-amendment-to-supply-agreement-with-the-ministry-of-health-of-israel-to-supply-additional-doses-of-mrna-vaccine-against-covid-19-mrna-1273\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/moderna-announces-amendment-to-supply-agreement-with-the-ministry-of-health-of-israel-to-supply-additional-doses-of-mrna-vaccine-against-covid-19-mrna-1273\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Moderna Announces Amendment to Supply Agreement with the Ministry of Health of Israel to Supply Additional Doses of mRNA Vaccine Against COVID-19 (mRNA-1273)","datePublished":"2020-12-04T13:30:17+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/moderna-announces-amendment-to-supply-agreement-with-the-ministry-of-health-of-israel-to-supply-additional-doses-of-mrna-vaccine-against-covid-19-mrna-1273\/"},"wordCount":1240,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/moderna-announces-amendment-to-supply-agreement-with-the-ministry-of-health-of-israel-to-supply-additional-doses-of-mrna-vaccine-against-covid-19-mrna-1273\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20201204005331r1&sid=flmnd&distro=nx&lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/moderna-announces-amendment-to-supply-agreement-with-the-ministry-of-health-of-israel-to-supply-additional-doses-of-mrna-vaccine-against-covid-19-mrna-1273\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/moderna-announces-amendment-to-supply-agreement-with-the-ministry-of-health-of-israel-to-supply-additional-doses-of-mrna-vaccine-against-covid-19-mrna-1273\/","name":"Moderna Announces Amendment to Supply Agreement with the Ministry of Health of Israel to Supply Additional Doses of mRNA Vaccine Against COVID-19 (mRNA-1273) - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/moderna-announces-amendment-to-supply-agreement-with-the-ministry-of-health-of-israel-to-supply-additional-doses-of-mrna-vaccine-against-covid-19-mrna-1273\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/moderna-announces-amendment-to-supply-agreement-with-the-ministry-of-health-of-israel-to-supply-additional-doses-of-mrna-vaccine-against-covid-19-mrna-1273\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20201204005331r1&sid=flmnd&distro=nx&lang=en","datePublished":"2020-12-04T13:30:17+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/moderna-announces-amendment-to-supply-agreement-with-the-ministry-of-health-of-israel-to-supply-additional-doses-of-mrna-vaccine-against-covid-19-mrna-1273\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/moderna-announces-amendment-to-supply-agreement-with-the-ministry-of-health-of-israel-to-supply-additional-doses-of-mrna-vaccine-against-covid-19-mrna-1273\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/moderna-announces-amendment-to-supply-agreement-with-the-ministry-of-health-of-israel-to-supply-additional-doses-of-mrna-vaccine-against-covid-19-mrna-1273\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20201204005331r1&sid=flmnd&distro=nx&lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20201204005331r1&sid=flmnd&distro=nx&lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/moderna-announces-amendment-to-supply-agreement-with-the-ministry-of-health-of-israel-to-supply-additional-doses-of-mrna-vaccine-against-covid-19-mrna-1273\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Moderna Announces Amendment to Supply Agreement with the Ministry of Health of Israel to Supply Additional Doses of mRNA Vaccine Against COVID-19 (mRNA-1273)"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/393492","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=393492"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/393492\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=393492"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=393492"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=393492"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}